Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 14/20 | 0.52 |
| ▸ | TLR7 | Q9NYK1 | 13/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4565184 | 0.87 | TLR8 (0.64) | TLR8TLR7 | |
| SCHEMBL4520421 | 0.84 | MAP4K4 (0.50) | TLR8TLR7MAP4K4NLRP3 | |
| SCHEMBL4532171 | 0.84 | TLR7 (0.56) | TLR8TLR7 | |
| SCHEMBL4525426 | 0.84 | TLR8 (0.44) | TLR8TLR7MAP4K4NLRP3APP | |
| SCHEMBL4565057 | 0.84 | TLR8 (0.44) | TLR8TLR7MAP4K4APP | |
| SCHEMBL4525416 | 0.82 | MAP4K4 (0.50) | TLR8TLR7MAP4K4APPKCNH2 | |
| SCHEMBL4531314 | 0.81 | TLR8 (0.53) | TLR8TLR7 | |
| SCHEMBL5121413 | 0.81 | MAP4K4 (0.47) | TLR8TLR7MAP4K4APP | |
| SCHEMBL4095651 | 0.80 | DHFR (0.43) | TLR8TLR7MAP4K4KCNH2 | |
| SCHEMBL4101030 | 0.80 | DHFR (0.41) | TLR8TLR7MAP4K4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232278-B2 | Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C | GILEAD SCIENCES, INC. (US) | 2012-07-31 | — | — | US | claimed |
| US-8232278-B2 | Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C | GILEAD SCIENCES, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20090131414-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C | GILEAD SCIENCES, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| EP-1899332-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C. | GILEAD SCIENCES, INC. (US) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006135993-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C. | GILEAD SCIENCES, INC. (US) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131414-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C | DPYD, TYMP, PNPO | TLR8 1791/4885TLR7 851/4885MAP4K4 3289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.